RIGL Rigel Pharmaceuticals
- 0.982
- +0.012+1.26%
Rigel Pharmaceuticals News
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Rigel Pharmaceuticals (RIGL), as it has been recently upgraded to a Zacks Rank #2 (Buy).
US$5.15 - That's What Analysts Think Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Is Worth After These Results
The analysts might have been a bit too bullish on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), given that the company fell short of expectations when it released its first-quarter results last week.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Rigel Pharmaceuticals (RIGL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.
HC Wainwright & Co. : Rigel Pharmaceuticals (RIGL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15 price target.
Earnings Call Summary | Rigel Pharmaceuticals(RIGL.US) Q1 2024 Earnings Conference
The following is a summary of the Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript:Financial Performance:Rigel reported a decrease in net product sales for TAVALISSE, with Q1 2024 s
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...
Rigel Pharmaceuticals | 10-Q: Quarterly report
Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, Vs. Street Est of $31.5M
04:16 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M
Rigel Pharmaceuticals Inc. Q1 Loss Decreases, but Misses Estimates
Rigel Pharmaceuticals 1Q Loss $8.25M >RIGL
Rigel Pharmaceuticals 1Q Loss $8.25M >RIGL
Press Release: Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., May 7, 2024 -- First quarter 2024 total revenue of $29.5 million, which i
Rigel Pharmaceuticals Q1 24 Earnings Conference Call At 4:30 PM ET
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on...
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. The recent drop has obliterate
Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients With Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 ...
Analysis
Price Target
No Data
